Steve Clifton

Lead Optimization toward Proof-of-Concept Tools for Huntington’s Disease within a 4-(1<i>H</i>-Pyrazol-4-yl)pyrimidine Class of Pan-JNK Inhibitors

John Wityak, Kevin F. McGee, Michael P. Conlon et al. · Journal of Medicinal Chemistry · 2015 · 38 citations

Pharmacy, Medicinal Chemistry, Pharmacology +17

Metabolism and Pharmacokinetics of JM6 in Mice: JM6 Is Not a Prodrug for Ro-61-8048

Maria Beconi, Dawn Yates, Kathryn A. Lyons et al. · Drug Metabolism and Disposition · 2012 · 33 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Neutrophil maturation rate determines the effects of dipeptidyl peptidase 1 inhibition on neutrophil serine protease activity

Philip Gardiner, Cecilia Wikell, Steve Clifton et al. · British Journal of Pharmacology · 2016 · 20 citations · Full text

Life Sciences, Immunology, Pharmacology +12